{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T06:02:31Z","timestamp":1776751351878,"version":"3.51.2"},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006538","name":"Canadian Arthritis Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006538","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000226","name":"Ontario Ministry of Health and Long-Term Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jbspin.2024.105732","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T19:00:18Z","timestamp":1712343618000},"page":"105732","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Retention of triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine compared to combination methotrexate and leflunomide in rheumatoid arthritis"],"prefix":"10.1016","volume":"91","author":[{"given":"Sankalp Virendrakumar","family":"Bhavsar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6154-0121","authenticated-orcid":false,"given":"Mohammad","family":"Movahedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Cesta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet E.","family":"Pope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Bombardier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2024.105732_bib0080","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2024.105732_bib0085","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(97)01300-7","article-title":"Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis","volume":"350","author":"Boers","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2024.105732_bib0090","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/art.21405","article-title":"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial","volume":"52","author":"Goekoop-Ruiterman","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2024.105732_bib0095","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/S0140-6736(98)08513-4","article-title":"Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group","volume":"353","author":"M\u00f6tt\u00f6nen","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2024.105732_bib0100","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM199605163342002","article-title":"Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications","volume":"334","author":"O\u2019Dell","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2024.105732_bib0105","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1002\/art.34498","article-title":"A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial","volume":"64","author":"Moreland","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2024.105732_bib0110","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","article-title":"Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial","volume":"144","author":"Kremer","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jbspin.2024.105732_bib0115","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/acr.23759","article-title":"Low persistence rates in patients with rheumatoid arthritis treated with triple therapy and adverse drug events associated with sulfasalazine","volume":"71","author":"Erhardt","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2024.105732_bib0120","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/imj.12896","article-title":"Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis","volume":"45","author":"Cummins","year":"2015","journal-title":"Intern Med J"},{"key":"10.1016\/j.jbspin.2024.105732_bib0125","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/1759720X16664324","article-title":"Combination leflunomide and methotrexate in refractory rheumatoid arthritis: a biologic sparing approach","volume":"8","author":"Hodkinson","year":"2016","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.jbspin.2024.105732_bib0130","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00296-021-04994-1","article-title":"Comparison between leflunomide and sulfasalazine based triple therapy in methotrexate refractory rheumatoid arthritis: an open-label, non-inferiority randomized controlled trial","volume":"42","author":"Belani","year":"2022","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jbspin.2024.105732_bib0135","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.semarthrit.2007.02.001","article-title":"Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use","volume":"37","author":"Proudman","year":"2007","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2024.105732_bib0140","first-page":"215","article-title":"Treatment patterns in rheumatoid arthritis after discontinuation of methotrexate: data from the Ontario best practices research initiative (OBRI)","volume":"36","author":"Pope","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105732_bib0145","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.3899\/jrheum.151136","article-title":"Agreement between rheumatologist and patient-reported adherence to methotrexate in a US rheumatoid arthritis registry","volume":"43","author":"Curtis","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105732_bib0150","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/acr.23255","article-title":"Rheumatoid arthritis treatment after methotrexate: the durability of triple therapy versus etanercept","volume":"69","author":"Peper","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X24000435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X24000435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T20:42:12Z","timestamp":1720644132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X24000435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1297319X24000435"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2024.105732","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retention of triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine compared to combination methotrexate and leflunomide in rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2024.105732","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie.","name":"copyright","label":"Copyright"}],"article-number":"105732"}}